APOA1 and atherosclerosis: In addition to reducing atherosclerosis, apoA-I has been proposed to be protective against nonischemic cardiomyopathies, thrombosis, diabetes, as well as diseases nonrelated to the cardiovascular system, such as cancer and neurological disorders (9).